Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Limiting Dilution Cloning – V 2.0

Posted on By


Biosimilars: SOP for Limiting Dilution Cloning – V 2.0


Standard Operating Procedure for Limiting Dilution Cloning in Biosimilar Development

Department Biosimilars
SOP No. SOP/BS/011/2025
Supersedes SOP/BS/011/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define a standard procedure for isolating single-cell-derived clones by limiting dilution cloning in order to establish monoclonal cell lines used in biosimilar product development.

2. Scope

This SOP applies to all R&D and cell line development personnel performing single-cell isolation for generating stable monoclonal cell populations expressing biosimilar proteins.

3. Responsibilities

  • Research Scientist: Designs and executes cloning strategy, monitors clone growth.
  • Lab Technician: Prepares media, dilutions, and culture plates.
  • QA Personnel: Verifies clone isolation records and ensures traceability.

4. Accountability

The Head of Cell Line Development is accountable for ensuring proper implementation and documentation of limiting dilution cloning procedures.

5. Procedure

5.1 Cell Preparation

  1. Harvest the transfected cells from log phase culture with viability ≥ 90%.
  2. Determine cell concentration using hemocytometer or automated cell counter.

5.2 Dilution Series Preparation

  1. Prepare serial dilutions in complete growth medium to achieve 1 cell/100 µL.
  2. Dispense 100 µL per well into a 96-well flat-bottom tissue culture plate.
  3. Use at least 3 plates to increase monoclonality chances.

5.3 Incubation and Observation

  1. Incubate the plates at 37°C with 5% CO2.
  2. Check wells daily under inverted microscope for single-cell outgrowth.
  3. Document wells showing growth from a single cell in Clone Seeding Log (Annexure-1).

5.4 Expansion of Positive Clones

  1. When cell number increases to 50–100 cells (typically 7–14 days), transfer to a 24-well plate.
  2. Gradually expand to 6-well, then T-25 flask with proper labeling and tracking.
  3. Confirm monoclonality via observation logs or automated imaging (if available).

5.5 Record Keeping

  1. Assign Clone IDs to successfully expanded clones.
  2. Record growth parameters, morphology, and well ID in Clone Tracking Record (Annexure-2).

5.6 Troubleshooting

  1. If multiple colonies are observed in a well, discard for cloning purposes.
  2. If no growth is observed after 14 days, mark as non-viable.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • CO2: Carbon Dioxide

7. Documents

  1. Clone Seeding Log (Annexure-1)
  2. Clone Tracking Record (Annexure-2)

8. References

  • ICH Q5D – Derivation and Characterization of Cell Substrates
  • WHO Guidelines for Cell Line Characterization
  • CDSCO Guidelines for Monoclonality Assurance

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Clone Seeding Log

Date Plate ID Well No. Cell Count Observation Recorded By
03/05/2025 LD-01 B6 1 Single Cell Observed Sunita Reddy

Annexure-2: Clone Tracking Record

Clone ID Source Plate Expansion Date Media Used Passage No. Status
CL-CHO-11 LD-01:B6 10/05/2025 CHO DMEM + 10% FBS 1 Active

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added expanded annexures and clarified single-cell criteria Annual review
See also  Biosimilars: SOP for Inoculation of Bioreactors - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Elixir Department: SOP for Sampling of Raw Materials for Elixirs – V 2.0
Next Post: Creams: SOP for Preventive Maintenance of Homogenization Systems – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version